Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.

AIM:The aim of this retrospective study was to determine whether glucose metabolism assessed by using Fluorine-18 (F-18) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) provides prognostic information independent of established prognostic factors in patients with E...

Full description

Bibliographic Details
Main Authors: Jae Pil Hwang, Ilhan Lim, Chang-Bae Kong, Dae Geun Jeon, Byung Hyun Byun, Byung Il Kim, Chang Woon Choi, Sang Moo Lim
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4839768?pdf=render
_version_ 1818059558693634048
author Jae Pil Hwang
Ilhan Lim
Chang-Bae Kong
Dae Geun Jeon
Byung Hyun Byun
Byung Il Kim
Chang Woon Choi
Sang Moo Lim
author_facet Jae Pil Hwang
Ilhan Lim
Chang-Bae Kong
Dae Geun Jeon
Byung Hyun Byun
Byung Il Kim
Chang Woon Choi
Sang Moo Lim
author_sort Jae Pil Hwang
collection DOAJ
description AIM:The aim of this retrospective study was to determine whether glucose metabolism assessed by using Fluorine-18 (F-18) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) provides prognostic information independent of established prognostic factors in patients with Ewing sarcoma. METHODS:We retrospectively reviewed the medical records of 34 patients (men, 19; women, 15; mean age, 14.5 ± 9.7 years) with pathologically proven Ewing sarcoma. They had undergone F-18 FDG PET/CT as part of a pretreatment workup between September 2006 and April 2012. In this analysis, patients were classified by age, sex, initial location, size, and maximum standardized uptake value (SUVmax). The relationship between FDG uptake and survival was analyzed using the Kaplan-Meier method with the log-rank test and Cox's proportional hazards regression model. RESULTS:The median survival time for all 34 subjects was 999 days and the median SUV by using PET/CT was 5.8 (range, 2-18.1). Patients with a SUVmax ≤ 5.8 survived significantly longer than those with a SUVmax > 5.8 (median survival time, 1265 vs. 656 days; p = 0.002). Survival was also found to be significantly related to age (p = 0.024), size (p = 0.03), and initial tumor location (p = 0.036). Multivariate analysis revealed that a higher SUVmax (p = 0.003; confidence interval [CI], 3.63-508.26; hazard ratio [HR], 42.98), older age (p = 0.023; CI, 1.34-54.80; HR, 8.59), and higher stage (p = 0.03; CI, 1.21-43.95; HR, 7.3) were associated with worse overall survival. CONCLUSIONS:SUVmax measured by pretreatment F-18-FDG PET/CT can predict overall survival in patients with Ewing sarcoma.
first_indexed 2024-12-10T13:18:26Z
format Article
id doaj.art-a67cdbf245a24b90af867f1ebf092942
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-10T13:18:26Z
publishDate 2016-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-a67cdbf245a24b90af867f1ebf0929422022-12-22T01:47:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01114e015328110.1371/journal.pone.0153281Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.Jae Pil HwangIlhan LimChang-Bae KongDae Geun JeonByung Hyun ByunByung Il KimChang Woon ChoiSang Moo LimAIM:The aim of this retrospective study was to determine whether glucose metabolism assessed by using Fluorine-18 (F-18) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) provides prognostic information independent of established prognostic factors in patients with Ewing sarcoma. METHODS:We retrospectively reviewed the medical records of 34 patients (men, 19; women, 15; mean age, 14.5 ± 9.7 years) with pathologically proven Ewing sarcoma. They had undergone F-18 FDG PET/CT as part of a pretreatment workup between September 2006 and April 2012. In this analysis, patients were classified by age, sex, initial location, size, and maximum standardized uptake value (SUVmax). The relationship between FDG uptake and survival was analyzed using the Kaplan-Meier method with the log-rank test and Cox's proportional hazards regression model. RESULTS:The median survival time for all 34 subjects was 999 days and the median SUV by using PET/CT was 5.8 (range, 2-18.1). Patients with a SUVmax ≤ 5.8 survived significantly longer than those with a SUVmax > 5.8 (median survival time, 1265 vs. 656 days; p = 0.002). Survival was also found to be significantly related to age (p = 0.024), size (p = 0.03), and initial tumor location (p = 0.036). Multivariate analysis revealed that a higher SUVmax (p = 0.003; confidence interval [CI], 3.63-508.26; hazard ratio [HR], 42.98), older age (p = 0.023; CI, 1.34-54.80; HR, 8.59), and higher stage (p = 0.03; CI, 1.21-43.95; HR, 7.3) were associated with worse overall survival. CONCLUSIONS:SUVmax measured by pretreatment F-18-FDG PET/CT can predict overall survival in patients with Ewing sarcoma.http://europepmc.org/articles/PMC4839768?pdf=render
spellingShingle Jae Pil Hwang
Ilhan Lim
Chang-Bae Kong
Dae Geun Jeon
Byung Hyun Byun
Byung Il Kim
Chang Woon Choi
Sang Moo Lim
Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.
PLoS ONE
title Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.
title_full Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.
title_fullStr Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.
title_full_unstemmed Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.
title_short Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.
title_sort prognostic value of suvmax measured by pretreatment fluorine 18 fluorodeoxyglucose positron emission tomography computed tomography in patients with ewing sarcoma
url http://europepmc.org/articles/PMC4839768?pdf=render
work_keys_str_mv AT jaepilhwang prognosticvalueofsuvmaxmeasuredbypretreatmentfluorine18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinpatientswithewingsarcoma
AT ilhanlim prognosticvalueofsuvmaxmeasuredbypretreatmentfluorine18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinpatientswithewingsarcoma
AT changbaekong prognosticvalueofsuvmaxmeasuredbypretreatmentfluorine18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinpatientswithewingsarcoma
AT daegeunjeon prognosticvalueofsuvmaxmeasuredbypretreatmentfluorine18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinpatientswithewingsarcoma
AT byunghyunbyun prognosticvalueofsuvmaxmeasuredbypretreatmentfluorine18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinpatientswithewingsarcoma
AT byungilkim prognosticvalueofsuvmaxmeasuredbypretreatmentfluorine18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinpatientswithewingsarcoma
AT changwoonchoi prognosticvalueofsuvmaxmeasuredbypretreatmentfluorine18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinpatientswithewingsarcoma
AT sangmoolim prognosticvalueofsuvmaxmeasuredbypretreatmentfluorine18fluorodeoxyglucosepositronemissiontomographycomputedtomographyinpatientswithewingsarcoma